The Endocannabinoid Signaling System in the CNS: A Primer

International Review of Neurobiology

Volumn 125, Issue , 2015, Pages 1-47

  Hillard, Cecilia J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

CB1 cannabinoid receptor; Degradation; Endocannabinoid; Synaptic plasticity; Synthesis

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; AMIDASE; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; ENDOCANNABINOID; ENDOCANNABINOID RECEPTOR; ETHANOLAMINE DERIVATIVE; FATTY ACID AMIDASE; HYDROLASE; LIPOPROTEIN LIPASE; N ACYL PHOSPHATIDYLETHANOLAMINE; N ACYL PHOSPHATIDYLETHANOLAMINE SPECIFIC PHOSPHOLIPASE D; N ACYLETHANOLAMINE; N ARACHIDONYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPASE D; UNCLASSIFIED DRUG;

BIOACCUMULATION; BIODEGRADATION; BIOSYNTHESIS; CATABOLISM; CENTRAL NERVOUS SYSTEM; CHEMICAL MODIFICATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HYDROLYSIS; LONG TERM DEPRESSION; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; ANIMAL; PHYSIOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM; ENDOCANNABINOIDS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84949035273     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.irn.2015.10.001     Document Type: Chapter

References (272)

1. Ahn K., Johnson D.S., Mileni M., Beidler D., Long J.Z., McKinney M.K., et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chemistry & Biology 2009, 16(4):411-420. 10.1016/j.chembiol.2009.02.013.
2. Ahn K.H., Mahmoud M.M., Kendall D.A. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. The Journal of Biological Chemistry 2012, 287(15):12070-12082. 10.1074/jbc.M111.316463.
3. Alexander J.P., Cravatt B.F. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. Journal of the American Chemical Society 2006, 128(30):9699-9704. 10.1021/ja062999h.
4. Arreaza G., Devane W.A., Omeir D.L., Sajnani G., Kunz J., Cravatt B.F., et al. The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine. Neuroscience Letters 1997, 234:59-62.
5. Bachur N.R., Masek K., Melmon K.L., Udenfriend S. Fatty acid amides of ethanolamine in mammalian tissues. The Journal of Biological Chemistry 1965, 240:1019-1024.
6. Bachur N.R., Udenfriend S. Microsomal synthesis of fatty acid amides. The Journal of Biological Chemistry 1966, 241(6):1308-1313.
7. Baggelaar M.P., Chameau P.J., Kantae V., Hummel J., Hsu K.L., Janssen F., et al. Highly selective, reversible inhibitor identified by comparative chemoproteomics modulates diacylglycerol lipase activity in neurons. Journal of the American Chemical Society 2015, 137(27):8851-8857. 10.1021/jacs.5b04883.
8. Baillie G.L., Horswill J.G., Anavi-Goffer S., Reggio P.H., Bolognini D., Abood M.E., et al. CB1 receptor allosteric modulators display both agonist and signaling pathway specificity. Molecular Pharmacology 2013, 83(2):322-338. 10.1124/mol.112.080879.
9. Bauer M., Chicca A., Tamborrini M., Eisen D., Lerner R., Lutz B., et al. Identification and quantification of a new family of peptide endocannabinoids (pepcans) showing negative allosteric modulation at CB1 receptors. The Journal of Biological Chemistry 2012, 287(44):36944-36967. 10.1074/jbc.M112.382481.
10. Bell R.L., Kennerly D.A., Stanford N., Majerus P.W. Diglyceride lipase: A pathway for arachidonate release from human platelets. Proceedings of the National Academy of Sciences of the United States of America 1979, 76(7):3238-3241.
11. Bisogno T., Cascio M.G., Saha B., Mahadevan A., Urbani P., Minassi A., et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochimica et Biophysica Acta 2006, 1761(2):205-212.
12. Bisogno T., Howell F., Williams G., Minassi A., Cascio M.G., Ligresti A., et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. The Journal of Cell Biology 2003, 163(3):463-468.
13. Bisogno T., Maccarrone M., De Petrocellis L., Jarrahian A., Finazzi-Agro A., Hillard C., et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. European Journal of Biochemistry 2001, 268(7):1982-1989.
14. Bisogno T., Melck D., De Petrocellis L., Di Marzo V. Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. Journal of Neurochemistry 1999, 72:2113-2119.
15. Bisogno T., Sepe N., Melck D., Maurelli S., De Petrocellis L., Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. The Biochemical Journal 1997, 322(Pt. 2):671-677.
16. Blankman J.L., Long J.Z., Trauger S.A., Siuzdak G., Cravatt B.F. ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(4):1500-1505. 10.1073/pnas.1217121110.
17. Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chemistry & Biology 2007, 14(12):1347-1356. 10.1016/j.chembiol.2007.11.006.
18. Bomar M.G., Galande A.K. Modulation of the cannabinoid receptors by hemopressin peptides. Life Sciences 2013, 92(8-9):520-524. 10.1016/j.lfs.2012.07.028.
19. Bouaboula M., Hilairet S., Marchand J., Fajas L., Le Fur G., Casellas P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. European Journal of Pharmacology 2005, 517(3):174-181. 10.1016/j.ejphar.2005.05.032.
20. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. The Journal of Biological Chemistry 1997, 272(35):22330-22339.
21. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., et al. Cannabinoid-receptor expression in human leukocytes. European Journal of Biochemistry 1993, 214(1):173-180.
22. Bowles N.P., Hill M.N., Bhagat S.M., Karatsoreos I.N., Hillard C.J., McEwen B.S. Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice. Neuroscience 2012, 204:83-89. 10.1016/j.neuroscience.2011.08.048.
23. Buczynski M.W., Parsons L.H. Quantification of brain endocannabinoid levels: Methods, interpretations and pitfalls. British Journal of Pharmacology 2010, 160(3):423-442. BPH787 [pii]. 10.1111/j.1476-5381.2010.00787.x.
24. Cadas H., di Tomaso E., Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. The Journal of Neuroscience 1997, 17(4):1226-1242.
25. Cadas H., Gaillet S., Beltramo M., Venance L., Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. The Journal of Neuroscience 1996, 16(12):3934-3942.
26. Cao Z., Mulvihill M.M., Mukhopadhyay P., Xu H., Erdelyi K., Hao E., et al. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 2013, 144:808-817. 10.1053/j.gastro.2012.12.028.
27. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. International Immunopharmacology 2002, 2(1):69-82.
28. Castillo P.E., Younts T.J., Chavez A.E., Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron 2012, 76(1):70-81. 10.1016/j.neuron.2012.09.020.
29. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. British Journal of Pharmacology 1992, 106:231-232.
30. Chanda P.K., Gao Y., Mark L., Btesh J., Strassle B.W., Lu P., et al. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Molecular Pharmacology 2010, 78(6):996-1003. mol.110.068304 [pii]. 10.1124/mol.110.068304.
31. Chavez A.E., Chiu C.Q., Castillo P.E. TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nature Neuroscience 2010, 13(12):1511-1518. nn.2684 [pii]. 10.1038/nn.2684.
32. Chevaleyre V., Castillo P.E. Heterosynaptic LTD of hippocampal GABAergic synapses: A novel role of endocannabinoids in regulating excitability. Neuron 2003, 38(3):461-472.
33. Chiang K.P., Gerber A.L., Sipe J.C., Cravatt B.F. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: Evidence for a link between defects in the endocannabinoid system and problem drug use. Human Molecular Genetics 2004, 13(18):2113-2119.
34. Chicca A., Marazzi J., Nicolussi S., Gertsch J. Evidence for bidirectional endocannabinoid transport across cell membranes. The Journal of Biological Chemistry 2012, 287(41):34660-34682. 10.1074/jbc.M112.373241.
35. Colodzin M., Bachur N.R., Weissbach H., Udenfriend S. Enzymatic formation of fatty acid amides of ethanolamine by rat liver microsomes. Biochemical and Biophysical Research Communications 1963, 10(2):165-170.
36. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(16):9371-9376.
37. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384(6604):83-87.
38. de Lago E., Petrosino S., Valenti M., Morera E., Ortega-Gutierrez S., Fernandez-Ruiz J., et al. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochemical Pharmacology 2005, 70(3):446-452.
39. Deutsch D.G., Glaser S.T., Howell J.M., Kunz J.S., Puffenbarger R.A., Hillard C.J., et al. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. The Journal of Biological Chemistry 2001, 276(10):6967-6973.
40. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 1988, 34(5):605-613.
41. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258(5090):1946-1949.
42. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. European Journal of Biochemistry 1999, 264(1):258-267.
43. Di S., Boudaba C., Popescu I.R., Weng F.J., Harris C., Marcheselli V.L., et al. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. The Journal of Physiology 2005, 569(Pt. 3):751-760.
44. Di S., Malcher-Lopes R., Halmos K.C., Tasker J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: A fast feedback mechanism. The Journal of Neuroscience 2003, 23(12):4850-4857.
45. Dincheva I., Drysdale A.T., Hartley C.A., Johnson D.C., Jing D., King E.C., et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nature Communications 2015, 6:6395. 10.1038/ncomms7395.
46. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(16):10819-10824.
47. Du H., Kwon I.K., Kim J. Neuregulin-1 impairs the long-term depression of hippocampal inhibitory synapses by facilitating the degradation of endocannabinoid 2-AG. The Journal of Neuroscience 2013, 33(38):15022-15031. 10.1523/JNEUROSCI.5833-12.2013.
48. Edwards D.A., Kim J., Alger B.E. Multiple mechanisms of endocannabinoid response initiation in hippocampus. Journal of Neurophysiology 2006, 95(1):67-75.
49. Engeli S., Lehmann A.C., Kaminski J., Haas V., Janke J., Zoerner A.A., et al. Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects. Obesity (Silver Spring) 2014, 22(5):E70-E76. 10.1002/oby.20728.
50. Farooqui A.A., Horrocks L.A. Nitric oxide synthase inhibitors do not attenuate diacylglycerol or monoacylglycerol lipase activities in synaptoneurosomes. Neurochemical Research 1997, 22(10):1265-1269.
51. Filis P., Kind P.C., Spears N. Implantation failure in mice with a disruption in Phospholipase C beta 1 gene: Lack of embryonic attachment, aberrant steroid hormone signalling and defective endocannabinoid metabolism. Molecular Human Reproduction 2013, 19(5):290-301. 10.1093/molehr/gas067.
52. Fiskerstrand T., H'Mida-Ben Brahim D., Johansson S., M'Zahem A., Haukanes B.I., Drouot N., et al. Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism. American Journal of Human Genetics 2010, 87(3):410-417. S0002-9297(10)00414-3 [pii]. 10.1016/j.ajhg.2010.08.002.
53. Fourgeaud L., Mato S., Bouchet D., Hemar A., Worley P.F., Manzoni O.J. A single in vivo exposure to cocaine abolishes endocannabinoid-mediated long-term depression in the nucleus accumbens. The Journal of Neuroscience 2004, 24(31):6939-6945.
54. Fowler C.J., Tiger G., Ligresti A., Lopez-Rodriguez M.L., Di Marzo V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis-A difficult issue to handle. European Journal of Pharmacology 2004, 492(1):1-11.
55. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiological Reviews 2003, 83(3):1017-1066.
56. Fu J., Bottegoni G., Sasso O., Bertorelli R., Rocchia W., Masetti M., et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nature Neuroscience 2012, 15(1):64-69. 10.1038/nn.2986.
57. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A., Rodriguez De Fonseca F., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003, 425(6953):90-93.
58. Fukaya M., Uchigashima M., Nomura S., Hasegawa Y., Kikuchi H., Watanabe M. Predominant expression of phospholipase Cbeta1 in telencephalic principal neurons and cerebellar interneurons, and its close association with related signaling molecules in somatodendritic neuronal elements. The European Journal of Neuroscience 2008, 28(9):1744-1759. EJN6495 [pii]. 10.1111/j.1460-9568.2008.06495.x.
59. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry 1995, 232(1):54-61.
60. Galli G.G., Multhaupt H.A., Carrara M., de Lichtenberg K.H., Christensen I.B., Linnemann D., et al. Prdm5 suppresses Apc(Min)-driven intestinal adenomas and regulates monoacylglycerol lipase expression. Oncogene 2014, 33(25):3342-3350. 10.1038/onc.2013.283.
61. Gamage T.F., Ignatowska-Jankowska B.M., Wiley J.L., Abdelrahman M., Trembleau L., Greig I.R., et al. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behavioural Pharmacology 2014, 25(2):182-185. 10.1097/FBP.0000000000000027.
62. Gao C., Tronson N.C., Radulovic J. Modulation of behavior by scaffolding proteins of the post-synaptic density. Neurobiology of Learning and Memory 2013, 105:3-12. 10.1016/j.nlm.2013.04.014.
63. Gao Y., Vasilyev D.V., Goncalves M.B., Howell F.V., Hobbs C., Reisenberg M., et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. The Journal of Neuroscience 2010, 30(6):2017-2024. 30/6/2017 [pii]. 10.1523/JNEUROSCI.5693-09.2010.
64. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 1964, 86:1646-1647.
65. Gasperi V., Ceci R., Tantimonaco M., Talamonti E., Battista N., Parisi A., et al. The fatty acid amide hydrolase in lymphocytes from sedentary and active subjects. Medicine and Science in Sports and Exercise 2014, 46(1):24-32. 10.1249/MSS.0b013e3182a10ce6.
66. Gauthier K.M., Baewer D.V., Hittner S., Hillard C.J., Nithipatikom K., Reddy D.S., et al. Endothelium-derived 2-arachidonylglycerol: An intermediate in vasodilatory eicosanoid release in bovine coronary arteries. American Journal of Physiology. Heart and Circulatory Physiology 2005, 288(3):H1344-H1351.
67. 2+ channel current. American Journal of Physiology. Heart and Circulatory Physiology 1999, 276(6 Pt. 2):H2085-H2093.
68. Gerdeman G.L., Ronesi J., Lovinger D.M. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nature Neuroscience 2002, 5(5):446-451.
69. Glaser S.T., Abumrad N.A., Fatade F., Kaczocha M., Studholme K.M., Deutsch D.G. Evidence against the presence of an anandamide transporter. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(7):4269-4274.
70. Glass M., Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. The Journal of Neuroscience 1997, 17:5327-5333.
71. Glass M., Northup J.K. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Molecular Pharmacology 1999, 56(6):1362-1369.
72. Golczak M., Kiser P.D., Sears A.E., Lodowski D.T., Blaner W.S., Palczewski K. Structural basis for the acyltransferase activity of lecithin:Retinol acyltransferase-like proteins. The Journal of Biological Chemistry 2012, 287(28):23790-23807. 10.1074/jbc.M112.361550.
73. Golech S.A., McCarron R.M., Chen Y., Bembry J., Lenz F., Mechoulam R., et al. Human brain endothelium: Coexpression and function of vanilloid and endocannabinoid receptors. Brain Research. Molecular Brain Research 2004, 132(1):87-92.
74. Gomez O., Sanchez-Rodriguez A., Le M., Sanchez-Caro C., Molina-Holgado F., Molina-Holgado E. Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways. British Journal of Pharmacology 2011, 163(7):1520-1532. 10.1111/j.1476-5381.2011.01414.x.
75. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., Hipkin R.W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. Molecular Pharmacology 2000, 57(5):1045-1050.
76. Goparaju S.K., Ueda N., Taniguchi K., Yamamoto S. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochemical Pharmacology 1999, 57(4):417-423.
77. Gray J.M., Vecchiarelli H.A., Morena M., Lee T.T., Hermanson D.J., Kim A.B., et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. The Journal of Neuroscience 2015, 35(9):3879-3892. 10.1523/JNEUROSCI.2737-14.2015.
78. Grimaldi P., Pucci M., Di Siena S., Di Giacomo D., Pirazzi V., Geremia R., et al. The faah gene is the first direct target of estrogen in the testis: Role of histone demethylase LSD1. Cellular and Molecular Life Sciences 2012, 69(24):4177-4190. 10.1007/s00018-012-1074-6.
79. Grimaldi P., Rossi G., Catanzaro G., Maccarrone M. Modulation of the endocannabinoid-degrading enzyme fatty acid amide hydrolase by follicle-stimulating hormone. Vitamins and Hormones 2009, 81:231-261. S0083-6729(09)81010-8 [pii]. 10.1016/S0083-6729(09)81010-8.
80. Grueter B.A., Brasnjo G., Malenka R.C. Postsynaptic TRPV1 triggers cell type-specific long-term depression in the nucleus accumbens. Nature Neuroscience 2010, 13(12):1519-1525. nn.2685 [pii]. 10.1038/nn.2685.
81. Guerciolini R. Mode of action of orlistat. International Journal of Obesity and Related Metabolic Disorders 1997, 21(Suppl. 3):S12-S23.
82. Gulyas A.I., Cravatt B.F., Bracey M.H., Dinh T.P., Piomelli D., Boscia F., et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. The European Journal of Neuroscience 2004, 20(2):441-458.
83. Hansen H.S., Moesgaard B., Hansen H.H., Petersen G. N-Acylethanolamines and precursor phospholipids-Relation to cell injury. Chemistry and Physics of Lipids 2000, 108(1-2):135-150.
84. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(7):3662-3665.
85. Haring M., Guggenhuber S., Lutz B. Neuronal populations mediating the effects of endocannabinoids on stress and emotionality. Neuroscience 2012, 204:145-158. 10.1016/j.neuroscience.2011.12.035.
86. Hashimotodani Y., Ohno-Shosaku T., Maejima T., Fukami K., Kano M. Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release. Neuropharmacology 2008, 54:58-67.
87. Hashimotodani Y., Ohno-Shosaku T., Tanimura A., Kita Y., Sano Y., Shimizu T., et al. Acute inhibition of diacylglycerol lipase blocks endocannabinoid-mediated retrograde signalling: Evidence for on-demand biosynthesis of 2-arachidonoylglycerol. The Journal of Physiology 2013, 591(Pt. 19):4765-4776. 10.1113/jphysiol.2013.254474.
88. Heimann A.S., Gomes I., Dale C.S., Pagano R.L., Gupta A., de Souza L.L., et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(51):20588-20593. 10.1073/pnas.0706980105.
89. Henry D.J., Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neuroscience Letters 1995, 186:91-94.
90. Herkenham M., Groen B.G., Lynn A.B., De Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Research 1991, 552(2):301-310.
91. Hermanson D.J., Gamble-George J.C., Marnett L.J., Patel S. Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends in Pharmacological Sciences 2014, 35(7):358-367. 10.1016/j.tips.2014.04.006.
92. Hermanson D.J., Hartley N.D., Gamble-George J., Brown N., Shonesy B.C., Kingsley P.J., et al. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nature Neuroscience 2013, 16(9):1291-1298. 10.1038/nn.3480.
93. Hill M.N., Kumar S.A., Filipski S.B., Iverson M., Stuhr K.L., Keith J.M., et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Molecular Psychiatry 2013, 18:1125-1135. 10.1038/mp.2012.90.
94. Hillard C.J. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins & Other Lipid Mediators 2000, 61(1-2):3-18.
95. Hillard C.J., Campbell W.B. Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. Journal of Lipid Research 1997, 38(12):2383-2398.
96. Hillard C.J., Edgemond W.S., Jarrahian A., Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. Journal of Neurochemistry 1997, 69(2):631-638.
97. Hillard C.J., Jarrahian A. Cellular accumulation of anandamide: Consensus and controversy. British Journal of Pharmacology 2003, 140(5):802-808.
98. Hillard C.J., Jarrahian A. Accumulation of anandamide: Evidence for cellular diversity. Neuropharmacology 2005, 48(8):1072-1078.
99. Hillard C.J., Manna S., Greenberg M.J., DiCamelli R., Ross R.A., Stevenson L.A., et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). The Journal of Pharmacology and Experimental Therapeutics 1999, 289(3):1427-1433.
100. Hillard C.J., Wilkison D.M., Edgemond W.S., Campbell W.B. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochimica et Biophysica Acta 1995, 1257(3):249-256.
101. Hirasawa M., Schwab Y., Natah S., Hillard C.J., Mackie K., Sharkey K.A., et al. Dendritically released transmitters cooperate via autocrine and retrograde actions to inhibit afferent excitation in rat brain. The Journal of Physiology 2004, 559(Pt. 2):611-624.
102. Ho Y.C., Lee H.J., Tung L.W., Liao Y.Y., Fu S.Y., Teng S.F., et al. Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. The Journal of Neuroscience 2011, 31(41):14600-14610. 10.1523/JNEUROSCI.2671-11.2011.
103. Hofer S.C., Ralvenius W.T., Gachet M.S., Fritschy J.M., Zeilhofer H.U., Gertsch J. Localization and production of peptide endocannabinoids in the rodent CNS and adrenal medulla. Neuropharmacology 2015, 10.1016/j.neuropharm.2015.03.021.
104. Hohmann A.G., Suplita R.L., Bolton N.M., Neely M.H., Fegley D., Mangieri R., et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005, 435(7045):1108-1112.
105. Horswill J.G., Bali U., Shaaban S., Keily J.F., Jeevaratnam P., Babbs A.J., et al. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB(1) receptors with hypophagic effects in rats. British Journal of Pharmacology 2007, 152(5):805-814.
106. Horvath E., Woodhams S.G., Nyilas R., Henstridge C.M., Kano M., Sakimura K., et al. Heterogeneous presynaptic distribution of monoacylglycerol lipase, a multipotent regulator of nociceptive circuits in the mouse spinal cord. The European Journal of Neuroscience 2014, 39(3):419-434. 10.1111/ejn.12470.
107. Howlett A.C. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sciences 1984, 35:1803-1810.
108. Howlett A.C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Molecular Pharmacology 1985, 27:429-436.
109. Howlett A.C., Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response of neuroblastoma cell membranes. Molecular Pharmacology 1984, 26:532-538.
110. Howlett A.C., Qualy J.M., Khachatrian L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Molecular Pharmacology 1986, 29:307-313.
111. Hu S.S., Mackie K. Distribution of the endocannabinoid system in the central nervous system. Handbook of Experimental Pharmacology 2015, 231:59-93. 10.1007/978-3-319-20825-1_3.
112. Huang G.Z., Woolley C.S. Estradiol acutely suppresses inhibition in the hippocampus through a sex-specific endocannabinoid and mGluR-dependent mechanism. Neuron 2012, 74(5):801-808. 10.1016/j.neuron.2012.03.035.
113. Ignatowska-Jankowska B.M., Baillie G.L., Kinsey S., Crowe M., Ghosh S., Owens R.A., et al. A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. Neuropsychopharmacology 2015, 10.1038/npp.2015.148.
114. Ignatowska-Jankowska B.M., Ghosh S., Crowe M.S., Kinsey S.G., Niphakis M.J., Abdullah R.A., et al. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: Antinociceptive activity without cannabimimetic side effects. British Journal of Pharmacology 2014, 171(6):1392-1407. 10.1111/bph.12298.
115. Jung K.M., Astarita G., Zhu C., Wallace M., Mackie K., Piomelli D. A key role for diacylglycerol lipase in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Molecular Pharmacology 2007, 72(3):612-621.
116. Jung K.M., Mangieri R., Stapleton C., Kim J., Fegley D., Wallace M., et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Molecular Pharmacology 2005, 68:1196-1202.
117. Kaczocha M., Glaser S.T., Deutsch D.G. Identification of intracellular carriers for the endocannabinoid anandamide. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(15):6375-6380. 0901515106 [pii]. 10.1073/pnas.0901515106.
118. Kaczocha M., Hermann A., Glaser S.T., Bojesen I.N., Deutsch D.G. Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. The Journal of Biological Chemistry 2006, 281(14):9066-9075.
119. Kaczocha M., Vivieca S., Sun J., Glaser S.T., Deutsch D.G. Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. The Journal of Biological Chemistry 2012, 287(5):3415-3424. 10.1074/jbc.M111.304907.
120. Kang R., Wan J., Arstikaitis P., Takahashi H., Huang K., Bailey A.O., et al. Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. Nature 2008, 456(7224):904-909. 10.1038/nature07605.
121. Kano M. Control of synaptic function by endocannabinoid-mediated retrograde signaling. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences 2014, 90(7):235-250.
122. Kapanda C.N., Masquelier J., Labar G., Muccioli G.G., Poupaert J.H., Lambert D.M. Synthesis and pharmacological evaluation of 2,4-dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors. Journal of Medicinal Chemistry 2012, 55(12):5774-5783. 10.1021/jm3006004.
123. Karlsson M., Reue K., Xia Y.R., Lusis A.J., Langin D., Tornqvist H., et al. Exon-intron organization and chromosomal localization of the mouse monoglyceride lipase gene. Gene 2001, 272(1-2):11-18.
124. Katayama K., Ueda N., Kurahashi Y., Suzuki H., Yamamoto S., Kato I. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochimica et Biophysica Acta 1997, 1347(2-3):212-218.
125. Katona I., Sperlagh B., Sik A., Kafalvi A., Vizi E.S., Mackie K., et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. The Journal of Neuroscience 1999, 19(11):4544-4558.
126. Katona I., Urban G.M., Wallace M., Ledent C., Jung K.M., Piomelli D., et al. Molecular composition of the endocannabinoid system at glutamatergic synapses. The Journal of Neuroscience 2006, 26(21):5628-5637.
127. Keimpema E., Tortoriello G., Alpar A., Capsoni S., Arisi I., Calvigioni D., et al. Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(5):1935-1940. 10.1073/pnas.1212563110.
128. Kim S.R., Chung Y.C., Chung E.S., Park K.W., Won S.Y., Bok E., et al. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: Neuroprotection versus neurotoxicity. Molecular Neurobiology 2007, 35(3):245-254.
129. Kim J., Isokawa M., Ledent C., Alger B.E. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. The Journal of Neuroscience 2002, 22(23):10182-10191.
130. King A.R., Duranti A., Tontini A., Rivara S., Rosengarth A., Clapper J.R., et al. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chemistry & Biology 2007, 14(12):1357-1365. 10.1016/j.chembiol.2007.10.017.
131. Kirilly E., Gonda X., Bagdy G. CB1 receptor antagonists: New discoveries leading to new perspectives. Acta Physiologica 2012, 205(1):41-60. 10.1111/j.1748-1716.2012.02402.x.
132. Kortleven C., Bruneau L.C., Trudeau L.E. Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. Neuropharmacology 2012, 63(6):983-991. 10.1016/j.neuropharm.2012.07.037.
133. Kreitzer A.C., Regehr W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 2001, 29(3):717-727.
134. Kurahashi Y., Ueda N., Suzuki H., Suzuki M., Yamamoto S. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase. Biochemical and Biophysical Research Communications 1997, 237(3):512-515.
135. Lappas M. Effect of pre-existing maternal obesity, gestational diabetes and adipokines on the expression of genes involved in lipid metabolism in adipose tissue. Metabolism 2014, 63(2):250-262. 10.1016/j.metabol.2013.10.001.
136. Laprairie R.B., Bagher A.M., Kelly M.E., Denovan-Wright E.M. Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor. British Journal of Pharmacology 2015, 10.1111/bph.13250.
137. Lee M.W., Kraemer F.B., Severson D.L. Characterization of a partially purified diacylglycerol lipase from bovine aorta. Biochimica et Biophysica Acta 1995, 1254(3):311-318.
138. Lee S.H., Ledri M., Toth B., Marchionni I., Henstridge C.M., Dudok B., et al. Multiple forms of endocannabinoid and endovanilloid signaling regulate the tonic control of GABA release. The Journal of Neuroscience 2015, 35(27):10039-10057. 10.1523/JNEUROSCI.4112-14.2015.
139. Leung K., Elmes M.W., Glaser S.T., Deutsch D.G., Kaczocha M. Role of FAAH-like anandamide transporter in anandamide inactivation. PLoS One 2013, 8(11):e79355. 10.1371/journal.pone.0079355.
140. Leung D., Saghatelian A., Simon G.M., Cravatt B.F. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 2006, 45(15):4720-4726.
141. Liedhegner E.S., Vogt C.D., Sem D.S., Cunningham C.W., Hillard C.J. Sterol carrier protein-2: Binding protein for endocannabinoids. Molecular Neurobiology 2014, 50:149-158. 10.1007/s12035-014-8651-7.
142. Ligresti A., Morera E., Van Der Stelt M., Monory K., Lutz B., Ortar G., et al. Further evidence for the existence of a specific process for the membrane transport of anandamide. The Biochemical Journal 2004, 380(Pt. 1):265-272.
143. Liu J., Wang L., Harvey-White J., Huang B.X., Kim H.Y., Luquet S., et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 2008, 54(1):1-7. S0028-3908(07)00157-8 [pii]. 10.1016/j.neuropharm.2007.05.020.
144. Liu J., Wang L., Harvey-White J., Osei-Hyiaman D., Razdan R., Gong Q., et al. A biosynthetic pathway for anandamide. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(36):13345-13350.
145. Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Molecular Pharmacology 2005, 67(1):15-19. mol.104.006353 [pii]. 10.1124/mol.104.006353.
146. Lograno M.D., Romano M.R. Cannabinoid agonists induce contractile responses through Gi/o-dependent activation of phospholipase C in the bovine ciliary muscle. European Journal of Pharmacology 2004, 494(1):55-62.
147. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nature Chemical Biology 2009, 5(1):37-44. nchembio.129 [pii]. 10.1038/nchembio.129.
148. Long J.Z., Nomura D.K., Cravatt B.F. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chemistry & Biology 2009, 16(7):744-753. S1074-5521(09)00176-8 [pii]. 10.1016/j.chembiol.2009.05.009.
149. Maccarrone M., Bari M., Di Rienzo M., Finazzi-Agro A., Rossi A. Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin. The Journal of Biological Chemistry 2003, 278(35):32726-32732.
150. Maccarrone M., De Petrocellis L., Bari M., Fezza F., Salvati S., Di Marzo V., et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Archives of Biochemistry and Biophysics 2001, 393(2):321-328.
151. Maccarrone M., Di Rienzo M., Finazzi-Agro A., Rossi A. Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3. The Journal of Biological Chemistry 2003, 278(15):13318-13324.
152. Maccarrone M., Gasperi V., Fezza F., Finazzi-Agro A., Rossi A. Differential regulation of fatty acid amide hydrolase promoter in human immune cells and neuronal cells by leptin and progesterone. European Journal of Biochemistry 2004, 271(23-24):4666-4676. 10.1111/j.1432-1033.2004.04427.x.
153. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:3825-3829.
154. Maejima T., Hashimoto K., Yoshida T., Aiba A., Kano M. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 2001, 31(3):463-475.
155. Mai P., Yang L., Tian L., Wang L., Jia S., Zhang Y., et al. Endocannabinoid system contributes to liver injury and inflammation by activation of bone marrow-derived monocytes/macrophages in a CB1-dependent manner. Journal of Immunology 2015, 195(7):3390-3401. 10.4049/jimmunol.1403205.
156. Malcher-Lopes R., Di S., Marcheselli V.S., Weng F.J., Stuart C.T., Bazan N.G., et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. The Journal of Neuroscience 2006, 26(24):6643-6650.
157. Marrs W.R., Blankman J.L., Horne E.A., Thomazeau A., Lin Y.H., Coy J., et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nature Neuroscience 2010, 13(8):951-957. nn.2601 [pii]. 10.1038/nn.2601.
158. Marsicano G., Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. The European Journal of Neuroscience 1999, 11(12):4213-4225.
159. Martin B.R., Cravatt B.F. Large-scale profiling of protein palmitoylation in mammalian cells. Nature Methods 2009, 6(2):135-138. 10.1038/nmeth.1293.
160. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346(6284):561-564.
161. Matyas F., Urban G.M., Watanabe M., Mackie K., Zimmer A., Freund T.F., et al. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 2008, 54(1):95-107. S0028-3908(07)00170-0 [pii]. 10.1016/j.neuropharm.2007.05.028.
162. McFarland M.J., Porter A.C., Rakhshan F.R., Rawat D.S., Gibbs R.A., Barker E.L. A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. The Journal of Biological Chemistry 2004, 279(40):41991-41997.
163. McFarland M.J., Terebova E.A., Barker E.L. Detergent-resistant membrane microdomains in the disposition of the lipid signaling molecule anandamide. The AAPS Journal 2006, 8(1):E95-E100.
164. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 1995, 50(1):83-90.
165. Milne G.M., Koe B.K., Johnson M.R. Stereospecific and potent analgetic activity for nantradol-A structurally novel, cannabinoid-related analgetic. NIDA Research Monograph 1979, 27:84-92.
166. Min R., Testa-Silva G., Heistek T.S., Canto C.B., Lodder J.C., Bisogno T., et al. Diacylglycerol lipase is not involved in depolarization-induced suppression of inhibition at unitary inhibitory connections in mouse hippocampus. The Journal of Neuroscience 2010, 30(7):2710-2715. 30/7/2710 [pii]. 10.1523/JNEUROSCI.BC-3622-09.2010.
167. Molina-Holgado E., Vela J.M., Arevalo-Martin A., Almazan G., Molina-Holgado F., Borrell J., et al. Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. The Journal of Neuroscience 2002, 22(22):9742-9753.
168. Mukhopadhyay B., Cinar R., Yin S., Liu J., Tam J., Godlewski G., et al. Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(15):6323-6328. 1017689108 [pii]. 10.1073/pnas.1017689108.
169. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
170. Murataeva N., Straiker A., Mackie K. Parsing the players: 2-Arachidonoylglycerol synthesis and degradation in the CNS. British Journal of Pharmacology 2014, 171(6):1379-1391. 10.1111/bph.12411.
171. Nasr M.L., Shi X., Bowman A.L., Johnson M., Zvonok N., Janero D.R., et al. Membrane phospholipid bilayer as a determinant of monoacylglycerol lipase kinetic profile and conformational repertoire. Protein Science 2013, 22(6):774-787. 10.1002/pro.2257.
172. Navarrete M., Araque A. Endocannabinoids mediate neuron-astrocyte communication. Neuron 2008, 57(6):883-893. S0896-6273(08)00116-5 [pii]. 10.1016/j.neuron.2008.01.029.
173. Navia-Paldanius D., Aaltonen N., Lehtonen M., Savinainen J.R., Taschler U., Radner F.P., et al. Increased tonic cannabinoid CB1R activity and brain region-specific desensitization of CB1R Gi/o signaling axis in mice with global genetic knockout of monoacylglycerol lipase. European Journal of Pharmaceutical Sciences 2015, 77:180-188. 10.1016/j.ejps.2015.06.005.
174. Nicolussi S., Chicca A., Rau M., Rihs S., Soeberdt M., Abels C., et al. Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: From ultrapotent to hyperpotent. Biochemical Pharmacology 2014, 92(4):669-689. 10.1016/j.bcp.2014.09.020.
175. Nicolussi S., Gertsch J. Endocannabinoid transport revisited. Vitamins and Hormones 2015, 98:441-485. 10.1016/bs.vh.2014.12.011.
176. Nicolussi S., Viveros-Paredes J.M., Gachet M.S., Rau M., Flores-Soto M.E., Blunder M., et al. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. Pharmacological Research 2014, 80:52-65. 10.1016/j.phrs.2013.12.010.
177. Nie J., Lewis D.L. Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. The Journal of Neuroscience 2001, 21(22):8758-8764.
178. Nomura D.K., Morrison B.E., Blankman J.L., Long J.Z., Kinsey S.G., Marcondes M.C., et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334(6057):809-813. 10.1126/science.1209200.
179. Nyilas R., Dudok B., Urban G.M., Mackie K., Watanabe M., Cravatt B.F., et al. Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. The Journal of Neuroscience 2008, 28(5):1058-1063. 28/5/1058 [pii]. 10.1523/JNEUROSCI.5102-07.2008.
180. Oddi S., Fezza F., Pasquariello N., D'Agostino A., Catanzaro G., De Simone C., et al. Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chemistry & Biology 2009, 16(6):624-632. S1074-5521(09)00151-3 [pii]. 10.1016/j.chembiol.2009.05.004.
181. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29(3):729-738.
182. Ohno-Shosaku T., Tsubokawa H., Mizushima I., Yoneda N., Zimmer A., Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. The Journal of Neuroscience 2002, 22(10):3864-3872.
183. Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. The Journal of Biological Chemistry 2004, 279(7):5298-5305.
184. Ortar G., Bisogno T., Ligresti A., Morera E., Nalli M., Di Marzo V. Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. Journal of Medicinal Chemistry 2008, 51:6970-6979. 10.1021/jm800978m.
185. Pamplona F.A., Ferreira J., Menezes de Lima O., Duarte F.S., Bento A.F., Forner S., et al. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(51):21134-21139. 10.1073/pnas.1202906109.
186. Pan B., Wang W., Long J.Z., Sun D., Hillard C.J., Cravatt B.F., et al. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) enhances retrograde endocannabinoid signaling. The Journal of Pharmacology and Experimental Therapeutics 2009, 331(2):591-597. jpet.109.158162 [pii]. 10.1124/jpet.109.158162.
187. Pan B., Wang W., Zhong P., Blankman J.L., Cravatt B.F., Liu Q.S. Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice. The Journal of Neuroscience 2011, 31(38):13420-13430. 10.1523/JNEUROSCI.2075-11.2011.
188. Panlilio L.V., Justinova Z., Goldberg S.R. Inhibition of FAAH and activation of PPAR: New approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacology & Therapeutics 2013, 138(1):84-102. 10.1016/j.pharmthera.2013.01.003.
189. Patel S., Carrier E.J., Ho W.S., Rademacher D.J., Cunningham S., Reddy D.S., et al. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. Journal of Lipid Research 2005, 46(2):342-349.
190. Patel S., Hillard C.J. Endocannabinoids as modulators of synaptic signaling. The cannabinoid receptors 2009, 281-308. Humana Press, New York. P.H. Reggio (Ed.).
191. Patricelli M.P., Cravatt B.F. Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. Biochemistry 1999, 38:14125-14130.
192. Pertwee R.G. Ligands that target cannabinoid receptors in the brain: From THC to anandamide and beyond. Addiction Biology 2008, 13(2):147-159. ADB108 [pii]. 10.1111/j.1369-1600.2008.00108.x.
193. Pickel V.M., Shobin E.T., Lane D.A., Mackie K. Cannabinoid-1 receptors in the mouse ventral pallidum are targeted to axonal profiles expressing functionally opposed opioid peptides and contacting N-acylphosphatidylethanolamine-hydrolyzing phospholipase D terminals. Neuroscience 2012, 227C:10-21. 10.1016/j.neuroscience.2012.07.050.
194. Pollandt S., Liu J., Orozco-Cabal L., Grigoriadis D.E., Vale W.W., Gallagher J.P., et al. Cocaine withdrawal enhances long-term potentiation induced by corticotropin-releasing factor at central amygdala glutamatergic synapses via CRF, NMDA receptors and PKA. The European Journal of Neuroscience 2006, 24(6):1733-1743. 10.1111/j.1460-9568.2006.05049.x.
195. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. The Journal of Pharmacology and Experimental Therapeutics 2002, 301(3):1020-1024.
196. Pratt P.F., Hillard C.J., Edgemond W.S., Campbell W.B. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. The American Journal of Physiology 1998, 274(1 Pt. 2):H375-H381.
197. Prescott S.M., Majerus P.W. Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. The Journal of Biological Chemistry 1983, 258(2):764-769.
198. Price M.R., Baillie G.L., Thomas A., Stevenson L.A., Easson M., Goodwin R., et al. Allosteric modulation of the cannabinoid CB1 receptor. Molecular Pharmacology 2005, 68(5):1484-1495.
199. Puente N., Cui Y., Lassalle O., Lafourcade M., Georges F., Venance L., et al. Polymodal activation of the endocannabinoid system in the extended amygdala. Nature Neuroscience 2011, 14(12):1542-1547. 10.1038/nn.2974.
200. Puffenbarger R.A., Kapulina O., Howell J.M., Deutsch D.G. Characterization of the 5'-sequence of the mouse fatty acid amide hydrolase. Neuroscience Letters 2001, 314(1-2):21-24.
201. Rahman I.A., Tsuboi K., Uyama T., Ueda N. New players in the fatty acyl ethanolamide metabolism. Pharmacological Research 2014, 86:1-10. 10.1016/j.phrs.2014.04.001.
202. Reguero L., Puente N., Elezgarai I., Ramos-Uriarte A., Gerrikagoitia I., Bueno-Lopez J.L., et al. Subcellular localization of NAPE-PLD and DAGL-alpha in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method. Histochemistry and Cell Biology 2014, 141(5):543-550. 10.1007/s00418-013-1174-x.
203. Reisenberg M., Singh P.K., Williams G., Doherty P. The diacylglycerol lipases: Structure, regulation and roles in and beyond endocannabinoid signalling. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 2012, 367(1607):3264-3275. 10.1098/rstb.2011.0387.
204. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 1994, 350(2-3):240-244.
205. Roloff A.M., Anderson G.R., Martemyanov K.A., Thayer S.A. Homer 1a gates the induction mechanism for endocannabinoid-mediated synaptic plasticity. The Journal of Neuroscience 2010, 30(8):3072-3081. 30/8/3072 [pii]. 10.1523/JNEUROSCI.4603-09.2010.
206. Ronesi J., Gerdeman G.L., Lovinger D.M. Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. The Journal of Neuroscience 2004, 24(7):1673-1679.
207. Rosenberger T.A., Farooqui A.A., Horrocks L.A. Bovine brain diacylglycerol lipase: Substrate specificity and activation by cyclic AMP-dependent protein kinase. Lipids 2007, 42(3):187-195. 10.1007/s11745-007-3019-7.
208. Ross R.A., Gibson T.M., Brockie H.C., Leslie M., Pashmi G., Craib S.J., et al. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. British Journal of Pharmacology 2001, 132(3):631-640.
209. Rouzer C.A., Marnett L.J. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: Cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chemical Reviews 2011, 111(10):5899-5921. 10.1021/cr2002799.
210. Ruehle S., Remmers F., Romo-Parra H., Massa F., Wickert M., Wortge S., et al. Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons: Distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions. The Journal of Neuroscience 2013, 33(25):10264-10277. 10.1523/JNEUROSCI.4171-12.2013.
211. Saghatelian A., Cravatt B.F. Discovery metabolite profiling-Forging functional connections between the proteome and metabolome. Life Sciences 2005, 77(14):1759-1766.
212. Saghatelian A., McKinney M.K., Bandell M., Patapoutian A., Cravatt B.F. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 2006, 45(30):9007-9015. 10.1021/bi0608008.
213. Sakurada T., Noma A. Subcellular localization and some properties of monoacylglycerol lipase in rat adipocytes. Journal of Biochemistry 1981, 90(5):1413-1419.
214. Salio C., Doly S., Fischer J., Franzoni M.F., Conrath M. Neuronal and astrocytic localization of the cannabinoid receptor-1 in the dorsal horn of the rat spinal cord. Neuroscience Letters 2002, 329(1):13-16.
215. Savinainen J.R., Saario S.M., Laitinen J.T. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiologica 2012, 204(2):267-276. 10.1111/j.1748-1716.2011.02280.x.
216. Savinainen J.R., Saario S.M., Niemi R., Jarvinen T., Laitinen J.T. An optimized approach to study endocannabinoid signaling: Evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. British Journal of Pharmacology 2003, 140(8):1451-1459.
217. Schlosburg J.E., Blankman J.L., Long J.Z., Nomura D.K., Pan B., Kinsey S.G., et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nature Neuroscience 2010, 13(9):1113-1119. nn.2616 [pii]. 10.1038/nn.2616.
218. Schmid P.C., Krebsbach R.J., Perry S.R., Dettmer T.M., Maasson J.L., Schmid H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Letters 1995, 375(1-2):117-120.
219. Schmid H.H., Schmid P.C., Natarajan V. N-acylated glycerophospholipids and their derivatives. Progress in Lipid Research 1990, 29(1):1-43.
220. Schmid H.H., Schmid P.C., Natarajan V. The N-acylation-phosphodiesterase pathway and cell signalling. Chemistry and Physics of Lipids 1996, 80(1-2):133-142.
221. Schmid P.C., Zuzarte-Augustin M.L., Schmid H.H.O. Properties of rat liver N-acylethanolamine amidohydrolase. The Journal of Biological Chemistry 1985, 260:14145-14149.
222. Scotchie J.G., Savaris R.F., Martin C.E., Young S.L. Endocannabinoid regulation in human endometrium across the menstrual cycle. Reproductive Sciences 2015, 22(1):113-123. 10.1177/1933719114533730.
223. Shinohara N., Uyama T., Jin X.H., Tsuboi K., Tonai T., Houchi H., et al. Enzymological analysis of the tumor suppressor A-C1 reveals a novel group of phospholipid-metabolizing enzymes. Journal of Lipid Research 2011, 52(11):1927-1935. 10.1194/jlr.M015081.
224. Shonesy B.C., Wang X., Rose K.L., Ramikie T.S., Cavener V.S., Rentz T., et al. CaMKII regulates diacylglycerol lipase-alpha and striatal endocannabinoid signaling. Nature Neuroscience 2013, 16(4):456-463. 10.1038/nn.3353.
225. Simon G.M., Cravatt B.F. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for beta-hydrolase 4 in this pathway. The Journal of Biological Chemistry 2006, 281(36):26465-26472.
226. Simon G.M., Cravatt B.F. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. The Journal of Biological Chemistry 2008, 283:9341-9349. M707807200 [pii]. 10.1074/jbc.M707807200.
227. Simon G.M., Cravatt B.F. Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Molecular BioSystems 2010, 6(8):1411-1418. 10.1039/c000237b.
228. Sipe J.C., Chiang K., Gerber A.L., Beutler E., Cravatt B.F. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(12):8394-8399.
229. Straiker A., Mackie K. Metabotropic suppression of excitation in murine autaptic hippocampal neurons. The Journal of Physiology 2007, 578(Pt. 3):773-785.
230. Straiker A., Mitjavila J., Yin D., Gibson A., Mackie K. Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model. Pharmacological Research 2015, 99:370-376. 10.1016/j.phrs.2015.07.017.
231. Strosznajder J., Singh H., Horrocks L.A. Monoacylglycerol lipase. Regulation and increased activity during hypoxia and ischemia. Neurochemical Pathology 1984, 2(2):139-147.
232. Suarez J., Bermudez-Silva F.J., Mackie K., Ledent C., Zimmer A., Cravatt B.F., et al. Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. The Journal of Comparative Neurology 2008, 509(4):400-421. 10.1002/cne.21774.
233. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications 1995, 215(1):89-97.
234. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., et al. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. European Journal of Biochemistry 1996, 240(1):53-62.
235. Sumislawski J.J., Ramikie T.S., Patel S. Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: A potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. Neuropsychopharmacology 2011, 36(13):2750-2761. 10.1038/npp.2011.166.
236. 2 and lysophospholipase D. The Biochemical Journal 2004, 380(Pt. 3):749-756.
237. Tanimura A., Yamazaki M., Hashimotodani Y., Uchigashima M., Kawata S., Abe M., et al. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 2010, 65(3):320-327. S0896-6273(10)00047-4 [pii]. 10.1016/j.neuron.2010.01.021.
238. Tarzia G., Duranti A., Tontini A., Piersanti G., Mor M., Rivara S., et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. Journal of Medicinal Chemistry 2003, 46(12):2352-2360.
239. Tornqvist H., Belfrage P. Purification and some properties of a monoacylglycerol-hydrolyzing enzyme of rat adipose tissue. The Journal of Biological Chemistry 1976, 251(3):813-819.
240. Tsou K., Nogueron M.I., Muthian S., Sanudo-Pena M.C., Hillard C.J., Deutsch D.G., et al. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neuroscience Letters 1998, 254(3):137-140.
241. Tsuboi K., Okamoto Y., Ikematsu N., Inoue M., Shimizu Y., Uyama T., et al. Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways. Biochimica et Biophysica Acta 2011, 1811(10):565-577. S1388-1981(11)00134-X [pii]. 10.1016/j.bbalip.2011.07.009.
242. Tuccinardi T., Granchi C., Rizzolio F., Caligiuri I., Battistello V., Toffoli G., et al. Identification and characterization of a new reversible MAGL inhibitor. Bioorganic & Medicinal Chemistry 2014, 22(13):3285-3291. 10.1016/j.bmc.2014.04.057.
243. Turu G., Hunyady L. Signal transduction of the CB1 cannabinoid receptor. Journal of Molecular Endocrinology 2010, 44(2):75-85. JME-08-0190 [pii]. 10.1677/JME-08-0190.
244. Turu G., Simon A., Gyombolai P., Szidonya L., Bagdy G., Lenkei Z., et al. The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity. The Journal of Biological Chemistry 2007, 282(11):7753-7757.
245. Turu G., Varnai P., Gyombolai P., Szidonya L., Offertaler L., Bagdy G., et al. Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors. The Journal of Biological Chemistry 2009, 284:16914-16921. M109.003681 [pii]. 10.1074/jbc.M109.003681.
246. Uchigashima M., Narushima M., Fukaya M., Katona I., Kano M., Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. The Journal of Neuroscience 2007, 27(14):3663-3676.
247. Ueda N., Tsuboi K., Uyama T. Enzymological studies on the biosynthesis of N-acylethanolamines. Biochimica et Biophysica Acta 2010, 1801(12):1274-1285. S1388-1981(10)00188-5 [pii]. 10.1016/j.bbalip.2010.08.010.
248. Ueda N., Yamanaka K., Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. The Journal of Biological Chemistry 2001, 276(38):35552-35557.
249. Urquhart P., Nicolaou A., Woodward D.F. Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases. Biochimica et Biophysica Acta 2015, 1851(4):366-376. 10.1016/j.bbalip.2014.12.015.
250. Uyama T., Inoue M., Okamoto Y., Shinohara N., Tai T., Tsuboi K., et al. Involvement of phospholipase A/acyltransferase-1 in N-acylphosphatidylethanolamine generation. Biochimica et Biophysica Acta 2013, 1831(12):1690-1701. 10.1016/j.bbalip.2013.08.017.
251. Vallee M., Vitiello S., Bellocchio L., Hebert-Chatelain E., Monlezun S., Martin-Garcia E., et al. Pregnenolone can protect the brain from cannabis intoxication. Science 2014, 343(6166):94-98. 10.1126/science.1243985.
252. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310(5746):329-332.
253. Vandevoorde S., Fowler C.J. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: Evidence that VDM11 acts as an FAAH substrate. British Journal of Pharmacology 2005, 145(7):885-893.
254. Vellani V., Petrosino S., De Petrocellis L., Valenti M., Prandini M., Magherini P.C., et al. Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. Neuropharmacology 2008, 55:1274-1279. S0028-3908(08)00034-8 [pii]. 10.1016/j.neuropharm.2008.01.010.
255. Vermeer L.M., Gregory E., Winter M.K., McCarson K.E., Berman N.E. Exposure to bisphenol A exacerbates migraine-like behaviors in a multibehavior model of rat migraine. Toxicological Sciences 2014, 137(2):416-427. 10.1093/toxsci/kft245.
256. Viader A., Blankman J.L., Zhong P., Liu X., Schlosburg J.E., Joslyn C.M., et al. Metabolic interplay between astrocytes and neurons regulates endocannabinoid action. Cell Reports 2015, 12(5):798-808. 10.1016/j.celrep.2015.06.075.
257. Vyvoda O.S., Rowe C.E. Glyceride lipases in nerve endings of guinea-pig brain and their stimulation by noradrenaline, 5-hydroxytryptamine and adrenaline. The Biochemical Journal 1973, 132(2):233-248.
258. Waleh N.S., Cravatt B.F., Apte-Deshpande A., Terao A., Kilduff T.S. Transcriptional regulation of the mouse fatty acid amide hydrolase gene. Gene 2002, 291(1-2):203-210.
259. Wang X., Horswill J.G., Whalley B.J., Stephens G.J. Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum. Molecular Pharmacology 2011, 79(4):758-767. mol.110.068197 [pii]. 10.1124/mol.110.068197.
260. Wang J., Okamoto Y., Morishita J., Tsuboi K., Miyatake A., Ueda N. Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-beta-lactamase family. The Journal of Biological Chemistry 2006, 281(18):12325-12335. 10.1074/jbc.M512359200.
261. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410(6828):588-592.
262. Wiskerke J., Irimia C., Cravatt B.F., De Vries T.J., Schoffelmeer A.N., Pattij T., et al. Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: An in vivo microdialysis study. ACS Chemical Neuroscience 2012, 3(5):407-417. 10.1021/cn300036b.
263. Wolfson M.L., Aisemberg J., Salazar A.I., Dominguez Rubio A.P., Vercelli C.A., Franchi A.M. Progesterone reverts LPS-reduced FAAH activity in murine peripheral blood mononuclear cells by a receptor-mediated fashion. Molecular and Cellular Endocrinology 2013, 381(1-2):97-105. 10.1016/j.mce.2013.07.020.
264. Won Y.J., Puhl H.L., Ikeda S.R. Molecular reconstruction of mGluR5a-mediated endocannabinoid signaling cascade in single rat sympathetic neurons. The Journal of Neuroscience 2009, 29(43):13603-13612. 29/43/13603 [pii]. 10.1523/JNEUROSCI.2244-09.2009.
265. Woodhams S.G., Wong A., Barrett D.A., Bennett A.J., Chapman V., Alexander S.P. Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. British Journal of Pharmacology 2012, 167(8):1609-1619. 10.1111/j.1476-5381.2012.02179.x.
266. Yang W., Di Vizio D., Kirchner M., Steen H., Freeman M.R. Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and non-raft membranes. Molecular & Cellular Proteomics: MCP 2010, 9(1):54-70. 10.1074/mcp.M800448-MCP200.
267. Yoshida T., Fukaya M., Uchigashima M., Miura E., Kamiya H., Kano M., et al. Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. The Journal of Neuroscience 2006, 26(18):4740-4751.
268. Yoshino H., Miyamae T., Hansen G., Zambrowicz B., Flynn M., Pedicord D., et al. Postsynaptic diacylglycerol lipase alpha mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. The Journal of Physiology 2011, 589(Pt. 20):4857-4884. jphysiol.2011.212225 [pii]. 10.1113/jphysiol.2011.212225.
269. Zhang H.Y., Gao M., Liu Q.R., Bi G.H., Li X., Yang H.J., et al. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America 2014, 111(46):E5007-E5015. 10.1073/pnas.1413210111.
270. 2+ or by metabotropic glutamate receptors appear to arise from different pools of diacylglycerol lipase. PLoS One 2011, 6(1):e16305. 10.1371/journal.pone.0016305.
271. Zhao L., Levine E.S. BDNF-endocannabinoid interactions at neocortical inhibitory synapses require phospholipase C signaling. Journal of Neurophysiology 2014, 111(5):1008-1015. 10.1152/jn.00554.2013.
272. Zhu C., Solorzano C., Sahar S., Realini N., Fung E., Sassone-Corsi P., et al. Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Molecular Pharmacology 2011, 79(4):786-792. 10.1124/mol.110.070201.